Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman MD, Leary CB, Lu WP, Al-Ani G, Chen X, Entenberg D, Oktay MH, Wang Y, Chun L, De Palma M, Jones JG, Flynn DL, Condeelis JS.

Mol Cancer Ther. 2017 Nov;16(11):2486-2501. doi: 10.1158/1535-7163.MCT-17-0241. Epub 2017 Aug 24.

PMID:
28838996
2.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA.

Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.

3.

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.

Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF.

Neuro Oncol. 2016 Sep;18(9):1230-41. doi: 10.1093/neuonc/now030. Epub 2016 Mar 9.

4.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.

Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub 2015 Sep 3.

5.

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.

Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, Telikepalli H, Vogeti L, Vogeti S, Yates KM, Chun L, Stewart LJ, Clare M, Flynn DL.

Mol Cancer Ther. 2015 Sep;14(9):2023-34. doi: 10.1158/1535-7163.MCT-14-1105. Epub 2015 Aug 18.

6.

Effective Collaboration Among Magnet Hospitals: A Win-Win for Nurses and Institutions.

Centrella-Nigro AM, Faber K, Wiklinski B, Bognar L, Flynn DL, LaForgia M.

Am J Nurs. 2015 Jul;115(7):50-4. doi: 10.1097/01.NAJ.0000467279.13447.ea. No abstract available.

PMID:
26110956
7.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.

J Med Chem. 2015 May 28;58(10):4165-79. doi: 10.1021/acs.jmedchem.5b00067. Epub 2015 May 12.

PMID:
25965804
8.

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.

Bai Y, Bandara G, Ching Chan E, Maric I, Simakova O, Bandara SN, Lu WP, Wise SC, Flynn DL, Metcalfe DD, Gilfillan AM, Wilson TM.

Leukemia. 2013 Feb;27(2):278-85. doi: 10.1038/leu.2012.218. Epub 2012 Jul 31. Review.

9.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ.

Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.

10.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart LJ, Van Etten RA, Flynn DL.

Cancer Cell. 2011 Apr 12;19(4):556-68. doi: 10.1016/j.ccr.2011.03.003.

11.

Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.

Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA.

Neoplasia. 2011 Jan;13(1):12-22.

12.

AXL regulates mesothelioma proliferation and invasiveness.

Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA.

Oncogene. 2011 Apr 7;30(14):1643-52. doi: 10.1038/onc.2010.555. Epub 2010 Dec 6.

PMID:
21132014
13.

Monomer-on-monomer (MoM) Mitsunobu reaction: facile purification utilizing surface-initiated sequestration.

Maity PK, Rolfe A, Samarakoon TB, Faisal S, Kurtz RD, Long TR, Sch├Ątz A, Flynn DL, Grass RN, Stark WJ, Reiser O, Hanson PR.

Org Lett. 2011 Jan 7;13(1):8-10. doi: 10.1021/ol1022382. Epub 2010 Dec 1.

14.

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.

Ahn YM, Clare M, Ensinger CL, Hood MM, Lord JW, Lu WP, Miller DF, Patt WC, Smith BD, Vogeti L, Kaufman MD, Petillo PA, Wise SC, Abendroth J, Chun L, Clark R, Feese M, Kim H, Stewart L, Flynn DL.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5793-8. doi: 10.1016/j.bmcl.2010.07.134. Epub 2010 Aug 3.

PMID:
20800479
15.

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase.

Walker JK, Selness SR, Devraj RV, Hepperle ME, Naing W, Shieh H, Kurambail R, Yang S, Flynn DL, Benson AG, Messing DM, Dice T, Kim T, Lindmark RJ, Monahan JB, Portanova J.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2634-8. doi: 10.1016/j.bmcl.2010.02.047. Epub 2010 Feb 14.

PMID:
20227876
16.

High-load, oligomeric dichlorotriazine: a versatile ROMP-derived reagent and scavenger.

Rolfe A, Probst DA, Volp KA, Omar I, Flynn DL, Hanson PR.

J Org Chem. 2008 Nov 21;73(22):8785-90. doi: 10.1021/jo801578f. Epub 2008 Oct 21.

17.

Oligomeric benzylsulfonium salts: facile benzylation via high-load ROMP reagents.

Zhang M, Flynn DL, Hanson PR.

J Org Chem. 2007 Apr 27;72(9):3194-8. Epub 2007 Apr 4.

PMID:
17407352
18.

Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.

Becker DP, Flynn DL, Moormann AE, Nosal R, Villamil CI, Loeffler R, Gullikson GW, Moummi C, Yang DC.

J Med Chem. 2006 Feb 9;49(3):1125-39.

PMID:
16451077
19.

Multipolymer solution-phase reactions: application to the Mitsunobu reaction.

Harned AM, He HS, Toy PH, Flynn DL, Hanson PR.

J Am Chem Soc. 2005 Jan 12;127(1):52-3.

PMID:
15631444
20.

High-load, soluble oligomeric carbodiimide: synthesis and application in coupling reactions.

Zhang M, Vedantham P, Flynn DL, Hanson PR.

J Org Chem. 2004 Nov 26;69(24):8340-4.

PMID:
15549805
21.

Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.

Becker DP, Flynn DL, Shone RL, Gullikson G.

Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12.

PMID:
15482914
22.
23.

Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist.

Becker DP, Flynn DL, Villamil CI.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3073-5.

PMID:
15149647
24.

High-load, ROMP-generated oligomeric bis-acid chlorides: design of soluble and insoluble nucleophile scavengers.

Moore JD, Byrne RJ, Vedantham P, Flynn DL, Hanson PR.

Org Lett. 2003 Nov 13;5(23):4241-4.

PMID:
14601970
25.

ROMP-generated oligomeric sulfonyl chlorides as versatile soluble scavenging agents.

Moore JD, Herpel RH, Lichtsinn JR, Flynn DL, Hanson PR.

Org Lett. 2003 Jan 23;5(2):105-7.

PMID:
12529116
26.

Ring-opening metathesis phase-trafficking (ROMpt) synthesis: multistep synthesis on soluble ROM supports.

Harned AM, Mukherjee S, Flynn DL, Hanson PR.

Org Lett. 2003 Jan 9;5(1):15-8. Erratum in: Org Lett. 2003 May 29;5(11):2015.

PMID:
12509879
27.

Recent advances in chemical library synthesis methodology.

Flynn DL, Berk SC, Makara GM.

Curr Opin Drug Discov Devel. 2002 Jul;5(4):580-93. Review.

PMID:
12197316
28.
29.

Scavenge-ROMP-filter: a facile strategy for soluble scavenging via norbornenyl tagging of electrophilic Reagents.

Moore JD, Harned AM, Henle J, Flynn DL, Hanson PR.

Org Lett. 2002 May 30;4(11):1847-9.

PMID:
12027629
30.

Phase-trafficking reagents and phase-switching strategies for parallel synthesis.

Flynn DL.

Med Res Rev. 1999 Sep;19(5):408-31. Review.

PMID:
10502743
31.

A mixed resin bed for the quenching and purification of tetrabutylammonium fluoride mediated desilylating reactions.

Parlow JJ, Vazquez ML, Flynn DL.

Bioorg Med Chem Lett. 1998 Sep 8;8(17):2391-4.

PMID:
9873547
32.

Chemically-tagged Mitsunobu reagents for use in solution-phase chemical library synthesis.

Starkey GW, Parlow JJ, Flynn DL.

Bioorg Med Chem Lett. 1998 Sep 8;8(17):2385-90.

PMID:
9873546
33.

Recent advances in polymer-assisted solution-phase chemical library synthesis and purification.

Flynn DL, Devraj RV, Parlow JJ.

Curr Opin Drug Discov Devel. 1998 Jul;1(1):41-50. No abstract available.

PMID:
19649788
34.

Recent advances in antiviral research: identification of inhibitors of the herpesvirus proteases.

Flynn DL, Abood NA, Holwerda BC.

Curr Opin Chem Biol. 1997 Aug;1(2):190-6. Review.

PMID:
9667847
35.

The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.

Flynn DL, Becker DP, Dilworth VM, Highkin MK, Hippenmeyer PJ, Houseman KA, Levine LM, Li M, Moormann AE, Rankin A, Toth MV, Villamil CI, Wittwer AJ, Holwerda BC.

Drug Des Discov. 1997 May;15(1):3-15. Review.

PMID:
9332827
36.

SC-53606, a potent and selective antagonist of 5-hydroxytryptamine4 receptors in isolated rat esophageal tunica muscularis mucosae.

Yang DC, Goldstin B, Moormann AE, Flynn DL, Gullikson GW.

J Pharmacol Exp Ther. 1993 Sep;266(3):1339-47.

PMID:
8396633
37.

SC-49518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamine4 receptor mechanism.

Gullikson GW, Virina MA, Loeffler RF, Yang DC, Goldstin B, Wang SX, Moummi C, Flynn DL, Zabrowski DL.

J Pharmacol Exp Ther. 1993 Jan;264(1):240-8.

PMID:
8380862
38.

SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.

Flynn DL, Zabrowski DL, Becker DP, Nosal R, Villamil CI, Gullikson GW, Moummi C, Yang DC.

J Med Chem. 1992 Apr 17;35(8):1486-9. No abstract available.

PMID:
1573641
39.

Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors.

Flynn DL, Belliotti TR, Boctor AM, Connor DT, Kostlan CR, Nies DE, Ortwine DF, Schrier DJ, Sircar JC.

J Med Chem. 1991 Feb;34(2):518-25.

PMID:
1847426
40.

Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.

Flynn DL, Capiris T, Cetenko WJ, Connor DT, Dyer RD, Kostlan CR, Nies DE, Schrier DJ, Sircar JC.

J Med Chem. 1990 Aug;33(8):2070-2. No abstract available.

PMID:
2115586
41.

The in vivo antiinflammatory effects of (E)-2,6-bis(1,1-dimethyl-ethyl)-4-[2-(5-methyl-1H-pyrazol-3-yl)ethenyl ] phenol (PD 127443) a novel dual inhibitor of 5-lipoxygenase and cyclooxygenase.

Schrier DJ, Adamchak MA, Boctor AM, Kostlan CR, Flynn DL, Jordan JH Jr, Lesch ME, Okonkwo GC.

Agents Actions. 1989 Jun;27(3-4):391-4. No abstract available.

PMID:
2552768
42.

Inhibition of human neutrophil 5-lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds.

Flynn DL, Rafferty MF, Boctor AM.

Prostaglandins Leukot Med. 1986 Oct;24(2-3):195-8.

PMID:
3467378
44.

Antimicrobial agents from higher plants. Antimicrobial agents from Peganum harmala seeds.

Al-Shamma A, Drake S, Flynn DL, Mitscher LA, Park YH, Rao GS, Simpson A, Swayze JK, Veysoglu T, Wu ST.

J Nat Prod. 1981 Nov-Dec;44(6):745-7. No abstract available.

PMID:
7334386
45.

Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.

Mitscher LA, Flynn DL, Gracey HE, Drake SD.

J Med Chem. 1979 Nov;22(11):1354-7.

PMID:
533883

Supplemental Content

Loading ...
Support Center